Foust Warren 4

What Happened Warren Foust, Interim Co-Chief Executive Officer and President & COO of STAAR Surgical (STAA), was granted 20,787 restricted stock units (RSUs) on February 2, 2026. The RSUs were awarded at no cash cost ($0.00) and are derivative awards that represent the right to receive one share of common stock per RSU upon vesting. This Form 4 notes the grant was made in connection with his appointment as Interim Co-CEO.

Key Details

• Transaction date: February 2, 2026; Form 4 filed February 4, 2026 (appears timely).
• Transaction type/code: A (award/grant) — 20,787 RSUs; acquisition price reported as $0.00 (derivative award).
• Vesting: 100% of the RSUs vest on August 1, 2026 (Footnote F2).
• Footnote: Each RSU converts to one share upon vesting (Footnote F1).
• Shares owned after transaction: Not disclosed in the filing.
• Remarks: Grant was made in connection with his appointment as Interim Co-CEO.

Context RSUs are a form of equity compensation that do not transfer shares or generate proceeds until they vest; no immediate sale or purchase occurred. Such awards are commonly used when executives take on new roles; the grant itself is informational rather than a direct buy/sell signal.